KKR and Manipal Group Announce USD 600 Mn Growth Financing Deal
The funding, arranged by KKR Capital Markets and backed by KKR's private credit and insurance platforms, will help the Manipal Group accelerate its long-term growth and expansion plans.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
KKR, a global investment firm, has partnered with Manipal Education and Medical Group (MEMG), a major Indian conglomerate, in a USD 600 million financing deal.
The funding, arranged by KKR Capital Markets and backed by KKR's private credit and insurance platforms, will help the Manipal Group accelerate its long-term growth and expansion plans.
Founded in 1953 by Padma Shri Dr TMA Pai, MEMG has grown into a diversified business with operations in healthcare, education, and health insurance. Its hospital arm, Manipal Health Enterprises, is one of India's largest multispecialty healthcare chains. The group also runs Manipal Academy of Higher Education, recognised as an Institute of Eminence by the Indian government.
Dr Ranjan Pai, Chairman of MEMG, said, "We are proud to welcome KKR as a strategic partner as we continue to build on Manipal's legacy in healthcare and education. KKR's longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us."
KKR's Asia Pacific Credit platform focuses on providing tailored financial solutions to top companies and entrepreneurs. Since 2019, it has committed over USD 8 billion across nearly 60 investments in the Asia Pacific region, representing more than USD 21 billion in total deal volume.
Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, said, "This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum."
MEMG's investment arm, Claypond Capital, has been actively investing in leading companies like PharmEasy, Zepto, FirstCry, and many others across healthcare, fintech, and consumer sectors.
Gaurav Trehan, Co-Head of KKR Asia Pacific, added, "We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai. Their long-standing impact across sectors is remarkable, and we look forward to supporting their continued success."
This strategic partnership marks a major step for both KKR and MEMG, aimed at strengthening India's healthcare and education ecosystem while supporting the Manipal Group's mission to reach millions more people.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Thames Water bonds plunge to record low as nationalisation threat grows
Thames Water's bonds have crashed to a record low after the Environment Secretary said it was stepping up contingency plans for the struggling utility giant. The price of Thames Water's debt fell to as low as 67p on Friday, down from 70p at the start of the month, as investors took flight amid fears the Government could nationalise the business. The market reaction was prompted largely by comments from Steve Reed last Thursday, who said that ministers were preparing to put Thames Water into a taxpayer-backed special administration regime. He said: 'The company remains financially stable, but we've stepped up our preparations and stand ready for all eventualities, as I've said before, including a special administration regime if that were to become necessary.' Falling bond prices signal that investors are also now bracing for the nationalisation of Thames Water, which remains on the brink despite a £17bn rescue proposal put forward by more than 100 of its most senior lenders. Talks are still ongoing over the potential bailout, although uncertainty is mounting after Mr Reed suggested the Government will not waive fines for Thames Water, which is one of the creditors' key demands. Pressures have also intensified after US private equity giant, KKR, unexpectedly abandoned its bid for the business earlier this month. Analysis of Thames Water's finances shows that a £250m bond due to mature in 2034 has been one of the hardest hit by the sell-off. Now valued at 67p, this is down from more than 80p two years ago. Falling bond prices in Britain's biggest water company will be a source of concern for the Government, which is seeking to attract global infrastructure investors as part of its bid to boost growth. Utilities are often deemed a safe haven by funds, therefore, the prospect of lenders incurring steep losses on Thames will be likely to damage investor appetite. There are huge numbers of creditors currently exposed to Thames Water, which has racked up a £16bn debt pile over the past decade, including a raft of different bonds. A special administration regime (SAR) would wipe out the bulk of Thames Water's borrowings, although it would also leave the Government forced to foot the bill for its running costs. A previous report estimated that an SAR could cost the taxpayer up to £4.1bn, piling further strain on the Government's stretched balance sheet. A report from JP Morgan last week said: 'Putting Thames into a SAR would be costly for the government and weaken its already tight fiscal position. 'Also, if Thames Water were nationalised, the Government would inherit all of the company's operational issues and be on the hook for any underperformance.' As well as billions of pounds in running costs, the creditors have calculated that Thames faces more than £1bn in fines and penalties over the coming years. However, despite the financial threat posed to investors and taxpayers, there are growing calls for the Government to nationalise Thames Water. Professor Dieter Helm, an economist and former government adviser, said last week that 'special administration will in the end most likely be necessary, and before 2029'. 'The Government and Ofwat made a major mistake at the outset in not calling in a special administrator,' he said. 'The leading bondholders have little practice experience in running a utility like Thames, and none has previous experience of a long-term major turnaround. 'They will no doubt have opportunities to take the money and run. All of this is likely before the next election, something that the Government should have in mind.' Thames Water was contacted for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.
Yahoo
3 hours ago
- Yahoo
Cyberway:The Common Choice for Digital Transformation of FMCG Fortune 500 Industries
GUANGZHOU, China, June 22, 2025 /PRNewswire/ -- Cyberway Information Technology Co., Ltd. (hereinafter referred to as "Cyberway") is a leading digital marketing empowerment expert. Since its establishment, Cyberway has focused on the digital marketing landscape in the consumer goods industry, with business coverage across China and the Asia-Pacific region. Upholding a philosophy of long-term partnership, Cyberway has consistently collaborated with numerous Fortune 500 companies and globally renowned brands, jointly driving successful digital transformation and leading the new wave of intelligent marketing in the industry. An Overview of Cyberway's Digital Marketing Services Cyberway's service offerings are centered on the evolving needs of enterprise development and adhere to the "ALL IN ONE" philosophy. Unlike traditional single-product or single-service approaches, Cyberway delivers a full lifecycle of support—from industry expert consulting, full-chain marketing system implementation, and international-standard IT operations, to cutting-edge AI transformation and AI Agent deployment—tailored to various stages of digital maturity. Cyber Insight: Industry-Expert Digital Marketing Consulting As one of the few software vendors offering digital marketing consulting, Cyberway brings a deep understanding of FMCG business models and processes. Our consulting services include feasibility studies, holistic digital planning, and comprehensive project evaluation—helping enterprises gain panoramic insight, implement the right systems, and take the first step toward sustainable business growth. Cyber 3A Model: The Industry's First Full-Chain Marketing Framework Integrating System, Data, and AI With a core of modular configurability, the Cyber 3A Model seamlessly connects front-end applications and back-end data. By integrating cutting-edge AI technologies, Cyberway enables businesses to build comprehensive intelligent marketing platforms, reshaping end-to-end digital capabilities. The model includes: Application Engine – Builds and connects full-chain marketing systems. Analytics Engine – Transforms data into strategic assets and drives decision intelligence. AI Engine (AI Middle Platform + AI Agent) – Accelerates real-world application of AI for enterprise use. Integrated and Efficient Digital Marketing Myetem Operations: Global Expertise, Local Execution Aligned with the Cyber 3A integrated platform concept, Cyberway offers comprehensive solutions for both system and data operations. These services ensure stable performance in day-to-day operations while addressing challenges of traditional IT management. With rich experience in overseas project delivery, Cyberway serves clients across Japan, South Korea, Singapore, Malaysia, Thailand, Australia, and New Zealand—offering deep insight into the unique demands of multinational FMCG enterprises. AI Evolution: Enabling AI Transformation and Building AI Agents Cyberway is committed to exploring AI technologies that enable enterprise digital transformation. In partnership with the School of Mathematics at Sun Yat-sen University, Cyberway co-established an AI research-industry-education innovation hub. Through collaboration with Dify, one of the top three global AI development platforms, Cyberway delivers a mature AI Middle Platform. This enables FMCG companies to skip building AI infrastructure from scratch and instead focus on business needs, Agent objectives, and integration of private data and knowledge—laying the foundation for enterprise-level AI Agents. From sales and marketing to R&D, IT, and operations, Cyberway empowers every function through "platform enablement + scenarios deep plowing" This approach transforms AI into real productivity, empowering business growth and accelerating enterprise-wide AI transformation. Future Trends: Where Will FMCG Enterprises Focus Their Digital + Intelligent Transformation Efforts? Build an Enterprise-Level AI Middle Platform and Incubate AI Agents – Unlock Data Potential and Drive Smart Decisions & Personalized Experiences With the maturation of AI technology, its application in the FMCG sector holds enormous potential. Building private AI Middle Platform and AI Agents ensures data security while delivering deep, scenario-based intelligence. A high-efficiency, flexible, and user-friendly AI development platform enables enterprises to swiftly build, customize, and deploy AI Agents across business dimensions—forming a "Generative AI Application Factory" to power the enterprise AI brain. AI Agents across the FMCG marketing value chain will become more than just tools—they will be intelligent assistants capable of autonomously performing complex tasks in various business scenarios, enhancing both operational efficiency and customer experience. Establish a Unified Master Data Management (MDM) Framework – Lay a Solid Data Foundation In the journey toward digital and AI transformation, data is a core asset. However, data that is fragmented across systems, inconsistently formatted, and of varying quality often becomes a major obstacle. Poor-quality data can lead to AI hallucinations, resulting in flawed outputs, misinformed decisions, and even wasted resources. Cyberway's MDM approach — built on the principles of unified structure, language, and standards — establishes an enterprise-grade data governance framework that ensures consistency, uniqueness, and compliance at the root. With end-to-end data governance that is standardized and AI-enabled, fragmented data is transformed into golden assets that fuel sustainable business growth. Build a Smart and Precision Marketing Expense Management Platform – Make Every Investment Count Marketing accounts for a large portion of costs in the FMCG industry, yet traditional management methods often suffer from poor budget allocation, low transparency, and difficulty in tracking effectiveness. Cyberway pioneered a three-stage marketing expense management framework—TPM (Transaction), TPE (Performance), and TPO (Optimization)—to address the varying needs of FMCG enterprises at different maturity levels. The platform seamlessly integrates with systems such as MDM, SAP, SFA, BI, DMS, POS, and OA, ensuring unified data flows and laying a solid foundation for AI-enabled finance operations. The platform is evolving with AI, embedding roles like Budget Planner, Campaign Mix Recommender, and Execution Optimizer—each powered by AI Agents—to serve targeted growth across brand, distributor, and retail layers. Build an Agile Product Innovation Collaboration Platform – Accelerate Product Launch and Market Fit In a product-driven era, rapid iteration and precision innovation are essential for maintaining competitiveness in FMCG. Traditional R&D processes are often slow, poorly coordinated, and disconnected from market feedback—hindering timely product launches. Cyberway developed the first product innovation collaboration platform tailored to the FMCG sector, pioneering a "Three-Stream Parallel" model—Marketing Campaigns, Launch Readiness, and Product Development. With end-to-end collaboration, standardized workflows, and data accumulation at its core, the platform leverages AI to make product innovation measurable, structured, and intelligent—boosting new product contribution rates. As an official ISV partner of the Tmall Innovation Lab, Cyberway offers a wealth of resources to help brands identify emerging trends, streamline R&D, and ensure successful product launches. Firmly rooted in the digital technology sector, Cyberway has established regional hubs in the Greater Bay Area, East China, and Southwest China, backed by a professional team of over 600 technical experts. Driven by innovation and technological leadership, Cyberway continues to invest in R&D and deepen its innovation capabilities, consistently improving product quality and market competitiveness. By staying aligned with AI and industry trends, Cyberway empowers enterprises to accelerate the growth of next-generation productivity and drive high-quality digital and intelligent transformation in the FMCG industry. Website: Tel：4001680262Email：Marketing@ View original content to download multimedia: SOURCE Cyberway Information Technology Co., Ltd.
